Mutations in Circulating Tumor Cells May Predict Clinical Outcomes in Patients with Metastatic Castrate-resistant Prostate Cancer

Published by W Butcher on

Various genetic alterations in circulating tumor cells (CTCs) were associated with clinical outcomes and resistance to hormone therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC), according to results published in Molecular Cancer Research, a journal of the American Association for Cancer Research.

Read More…

Categories: Uncategorized

0 Comments

Leave a Reply

Avatar placeholder

Your email address will not be published.